Trials / Completed
CompletedNCT00160225
Study to Evaluate the Efficacy and Safety of Daglutril Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension
A Randomized, Double-Blind, Placebo Controlled, Two-Treatment and Two-Period Cross-Over, Mono-Center Study to Evaluate the Efficacy and Safety of Daglutril 300 mg Once Daily Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the end of treatment effect of Daglutril compared to placebo on top of losartan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daglutril |
Timeline
- Start date
- 2005-07-01
- First posted
- 2005-09-12
- Last updated
- 2007-11-14
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT00160225. Inclusion in this directory is not an endorsement.